BioNetwork West 2015 (past event)
October 26 - 28, 2015
Contact Us: 1.888.482.6012
Chris Gambale
President
Global GXP Solutions
Check out the incredible speaker line-up to see who will be joining Chris.
Download The Latest AgendaChange Compliance to Regulatory
Friday, March 10th, 2017
09:00 Partnering Innovation Ice Breaker Roundtable Discussions
Get to know others with similar interests as you. Choose the topic most important to your business needs. You'll sit with 10 - 20 others seeking similar opportunities to debate the advantages and challenges assocatied with your chosen area, and make more connections!
#1 Valuation Strategies To Optimize Deal Terms And Structures
Kelly P. Powell, VP, Corporate Development, Orexigen Therapeutics
- Exploring valuation techniques to arrive at preferred deal terms (e.g. comparables, invested capital, discounted cash flow, etc.)
- When to use various techniques, as well as associated pitfalls
- How to use financial models to generate mutually beneficial deal structures
- Considerations for harmonizing your qualitative and quantitative partnering objectives
Christopher Gambale, President, Global GxP Solutions
- Building or modifying quality systems to incorporate new technology and new scientific platforms - Managing vendor quality risks through effective audit programs
- Improving speed to market through effective and efficient launches in a compliant manner
- Addressing existing Regulatory enforcement actions hamping your innovation and preventing new ones
- Preparation to move from an R&D setting or paper based system to an electronic system
- Essential elements necessary for a successful system implementation, cultural adoption, and long-term success in a complaint quality management system
- Quality strategy and project management
Gerry McCluskey, VP, Business Development and Alliance Management, Horizon Pharma
- How can BD and alliance management functions work most effectively together?
- How to avoid common pitfalls in alliance management
- Exploiting alliance management opportunities
Priyanka Rohatgi, Director, Baxter Ventures
- How has traditional venture capital changed over the past year, and what are expectations for the near- and far-term future?
- Exploring the emergence of venture capital groups associated with large provider organizations; what are their objectives in the current biopharma space?
- Discovering how the relationships among Big Pharma, biotechs, and VC are evolving
#5 In-Licensing: Winning Deals In A Highly Competitive Environment
Kalpana Gupta, Director of Business Development, Regeneron